TBPMF News and Press, Tetra Bio-Pharma Inc From 05/05/22

Tetra Bio-Pharma and Cannvalate Enter Into Partnership Canada NewsWire Cannvalate to invest CAD$7.5M in Tetra. Cannvalate to launch and manage QIXLEEF™ and CAUMZ™ clinical trials in Australia . The Company to benefit from a 43.5% tax credi...

Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA Canada NewsWire The Type C meeting with the FDA provides guidance to strengthen QIXLEEF™ nonclinical and toxicological data package for marketing approval. OTTAWA, ON , ...

Tetra Bio-Pharma (OTCQB:TBPMF), a development-stage biopharmaceutical company focused on cannabinoid-derived candidates, announced on Monday that Health Canada greenlighted an amendment to a Phase 1 study designed to evaluate cannabidiol (CBD) in adults. The company has partnered with Dr. Jut...

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD Canada NewsWire Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled...

Tetra Bio-Pharma Provides Management Update Canada NewsWire Significant reduction in cash burn rate Preliminary data on QIXLEEF™ safety and efficacy Update on REDUVO™ New Drug Submission Update on ARDS-003 preclinical SARS-CoV-2 ...

Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement Canada NewsWire OTTAWA, ON , Feb. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cann...

Tetra Bio-Pharma (OTCQB:TBPMF) announced the approval of a C$4.5M participative loan from the ministère de l'Économie et de l'Innovation under the BioMed Propulsion Program, managed by Investissement Québec. The company said the funding will support the development of ARDS-003 ...

Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec Canada NewsWire MONTREAL , Feb. 16, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a...

TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercializati...

Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna Canada NewsWire The proposed partnership will encompass three potential strategic pillars across supply of API, commercialization of prescription products, and co-development of pharmaceutical drug cand...